anifrolumab Report issue

Biologics mAb Approved FDA Fast Track FDA
AACT ChEMBL DrugBank

Active Ingredient History

NOW
  • Now
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

anifrolumab | medi-546

Organizations (13)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Arthritis, Rheumatoid (Phase 2)

Healthy Volunteers (Phase 1)

Lupus Erythematosus, Systemic (Phase 3)

Lupus Nephritis (Phase 3)

Pharmacokinetics (Phase 1)

Safety (Phase 1)

Scleroderma, Systemic (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue